We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“It is still early days but this is an extremely exciting milestone. These findings show the technology works, is safe and helps lower cholesterol to levels similar to medicines we currently have. The therapy has the potential to provide a 'one and done' approach to a very common condition, which would be transformative in preventing heart attacks and strokes over the long term.”
“Twenty years ago, genetics showed us that people born with PCSK9 naturally turned off have low LDL-C for life and are remarkably protected from heart attack, yet today's chronic therapies struggle to deliver this lifelong lowering. The Heart-2 results provide early clinical evidence that a single dose of VERVE-102 may mimic the LDL-C lowering effects of PCSK9 cardioprotective variants, potentially transforming cardiovascular care from chronic management to a one-time treatment.”
“What motivated us is the fact that most patients who are at high cardiovascular risk don't achieve and maintain their LDL goals, and the real challenge is that the current treatment model relies on chronically administered therapies—daily pills, intermittent injections. These treatments work to lower LDL, but the real-world efficacy is limited by high discontinuation rates.”
No takes yet. Share an insight, caveat, or question.
Vafai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: